Mr. Jeroen Wissink , CEO of U-Needle, will attend ATTD 2018 in Vienna on February 14-17, 2018. Please send us an email if you would like to meet up with him and learn more about U-Needle.
U-Needle develops proprietary microneedle technology applied in intradermal infusion devices for diabetes. The advanced microneedles technology facilitates faster insulin and peptide absorption via patient friendly intradermal injection. The needles do not require lubricant and remain atom-sharp upon multiple injections..
Please visite our website for further information.